Praxis Precision Medicines, Inc. Common Stock
PRAX
$370.16
+15.95%
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, leveraging its proprietary Cerebrum and Solidus platforms. The company is a niche player in the CNS space with a diversified pipeline targeting movement disorders and epilepsy, including lead candidates Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The current investor narrative centers on the FDA's acceptance of its New Drug Application for essential tremor, setting up a potential 2027 approval, alongside significant institutional investment and a massive stock surge of over 700% in the past year, reflecting high expectations for its pipeline's commercial potential.…
PRAX
Praxis Precision Medicines, Inc. Common Stock
$370.16
Related headlines
Investment Opinion: Should I buy PRAX Today?
Based on the analysis, I rate PRAX as a Buy, driven by the FDA acceptance for essential tremor and the potential for a 2027 approval, which could transform the company into a commercial-stage player. The consensus rating is 'Strong Buy' with an average price target of $610.05, implying 98.2% upside from the current price of $307.83. This upside, combined with the diversified pipeline and strong institutional backing, supports a bullish stance.
Sign up to view all
PRAX 12-Month Price Forecast
The AI assessment is bullish, driven by the FDA acceptance and strong analyst support. However, confidence is medium due to the high valuation and binary nature of regulatory decisions. The stock's 467.7% surge over the past year already prices in much of the good news, but the potential for a successful approval and commercial launch could drive further gains. Key factors to monitor include FDA review progress, clinical data readouts, and cash burn rate. An upgrade to high confidence would require positive phase 3 data or early approval, while a downgrade would occur if regulatory setbacks emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Praxis Precision Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $604.84 and implied upside of +63.4% versus the current price.
Average Target
$604.84
0 analysts
Implied Upside
+63.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$162 - $1201
Analyst target range
Praxis Precision Medicines is covered by 19 analysts, with a consensus recommendation of 'Strong Buy' and a mean rating of 1.47 (where 1 is Strong Buy and 5 is Sell). The average price target is $610.05, implying a substantial 98.2% upside from the current price of $307.83. The analyst sentiment is overwhelmingly bullish, with recent actions from firms like Needham, Truist, and HC Wainwright reiterating Buy ratings, while only Wedbush maintains an Underperform.
Bulls vs Bears: PRAX Investment Factors
Praxis Precision Medicines presents a high-risk, high-reward opportunity. The bull case is anchored by FDA acceptance for essential tremor, a diversified pipeline, and strong analyst and institutional support, with an average target implying 98% upside. However, the bear case highlights the pre-revenue status, accelerating losses, and a valuation that prices in perfection. Currently, the bull side has stronger evidence given the regulatory progress and analyst consensus, but the extreme volatility and dependence on binary FDA outcomes make this a speculative investment. The most critical tension is whether the pipeline's clinical and commercial success can justify the premium valuation, as any setback could lead to a dramatic repricing.
Bullish
- FDA Acceptance for Essential Tremor: The FDA accepted Praxis's New Drug Application for Ulixacaltamide in essential tremor, setting a clear path to a potential 2027 approval. This de-risks the lead program and validates the clinical data, a major catalyst that drove the stock up over 700% in the past year.
- Strong Analyst Conviction: With 19 analysts covering, the consensus is 'Strong Buy' with a mean rating of 1.47 (1=Strong Buy). The average price target of $610.05 implies 98.2% upside from the current price of $307.83, reflecting high expectations for pipeline success.
- Diversified CNS Pipeline: Praxis has four clinical-stage candidates (Ulixacaltamide, Relutrigine, Vormatrigine, Elsunersen) across movement disorders and epilepsy. This diversification reduces single-asset risk and provides multiple shots on goal, with a potential $20 billion+ neurology market opportunity.
- Institutional Backing: Major institutional investors have made significant bets, including a $266 million investment and a stake nearing $600 million. This signals strong conviction from sophisticated investors, supporting the stock's momentum and providing a floor under the share price.
Bearish
- Pre-Revenue with Accelerating Losses: Praxis has zero revenue and a net loss of $92.6 million in Q1 2026, up from $69.3 million in Q1 2025. R&D expenses rose to $78.0 million from $60.8 million, indicating accelerating cash burn as the pipeline advances, with no near-term revenue visibility.
- Extreme Valuation Premium: The price-to-book ratio of 7.55x is a significant premium to the biotech industry average of 3-4x. This implies the market is pricing in substantial future success, leaving little room for error; any clinical setback could trigger a sharp de-rating.
- High Volatility and Overextension: With a beta of 2.76, the stock is nearly three times more volatile than the market. Trading at 84% of its 52-week range, it has surged 467.7% in the past year, suggesting potential overextension and vulnerability to profit-taking or negative news.
- Regulatory and Clinical Risk: The stock's fate hinges on FDA approval decisions. Any delay, complete response letter, or unfavorable clinical data could devastate the stock, as seen in the biotech sector. The 52-week low of $37.19 illustrates the potential downside if expectations unravel.
PRAX Technical Analysis
Praxis Precision Medicines has exhibited a dramatic uptrend over the past year, with the stock surging 467.7% over the 1-year period, far outpacing the S&P 500's 18.2% gain. The current price of $307.83 sits at 84% of its 52-week range (between $37.19 low and $366.52 high), indicating the stock remains near its highs, suggesting strong momentum but also potential overextension. The stock's beta of 2.76 implies it is significantly more volatile than the market, amplifying both upside and downside moves.
Beta
2.78
2.78x market volatility
Max Drawdown
-36.3%
Largest decline past year
52-Week Range
$37-$383
Price range past year
Annual Return
+661.6%
Cumulative gain past year
| Period | PRAX Return | S&P 500 |
|---|---|---|
| 1m | +14.3% | +2.8% |
| 3m | +12.2% | +4.2% |
| 6m | +15.8% | +11.3% |
| 1y | +661.6% | +21.5% |
| ytd | +29.2% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PRAX Fundamental Analysis
Praxis Precision Medicines is a pre-revenue biotech, with zero revenue in the most recent quarter (Q1 2026) and a net loss of $92.6 million, consistent with its clinical-stage status. The company's R&D expenses were $78.0 million in Q1 2026, up from $60.8 million in Q1 2025, reflecting increased investment in its pipeline. The net loss widened from $69.3 million in Q1 2025 to $92.6 million in Q1 2026, indicating accelerating cash burn as the company advances its late-stage programs.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-282905000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PRAX Overvalued?
Given the company's negative net income, the price-to-sales ratio is not meaningful (PS ratio of 0), so I selected the price-to-book ratio as the primary valuation metric, which stands at 7.55x. This is a premium to the biotech industry average of around 3-4x, reflecting the market's high expectations for the pipeline's potential. The forward PE of -31.88x and trailing PE of -21.86x are both negative, but the gap between them suggests the market expects losses to narrow, as the forward multiple is less negative.
PE
-21.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Praxis has no revenue, and its net loss widened from $69.3 million in Q1 2025 to $92.6 million in Q1 2026, with R&D expenses increasing 28% year-over-year. The company's free cash flow is -$282.9 million TTM, and while it has a strong current ratio of 10.22 and no debt, the cash burn rate implies a finite runway. If clinical milestones are delayed, the company may need to raise capital through dilutive equity offerings, which could pressure the stock. Additionally, the negative earnings and lack of profitability mean the valuation is entirely dependent on future expectations, leaving no margin of safety if those expectations are not met.